These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1810444)

  • 1. Interferons in the treatment of malignancies.
    Kardamakis D
    In Vivo; 1991; 5(6):589-97. PubMed ID: 1810444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological monitoring and clinical trials of biological response modifiers.
    Baseler MW; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():231-50. PubMed ID: 1931445
    [No Abstract]   [Full Text] [Related]  

  • 3. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alpha interferons--new therapeutic modalities].
    Bajcetić M; Zigon N; Samardzić R; Beleslin DB
    Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the ATP-cell viability assay for assessment of biologic response modifiers in gynecologic cancer.
    Angioli R; Sevin BU
    Contrib Gynecol Obstet; 1994; 19():166-78. PubMed ID: 7995048
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D; Wadler S
    Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):309-11. PubMed ID: 9660037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of multiple sclerosis with interferons].
    Nogales-Gaete J; Arriagada C
    Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cytokine production of breast cancer patients treated with interferons.
    Barak V; Kalickman I; Nisman B; Farbstein H; Fridlender ZG; Baider L; Kaplan A; Stephanos S; Peretz T
    Cytokine; 1998 Dec; 10(12):977-83. PubMed ID: 10049522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The interferon system. A review of biological principles and clinical uses].
    Schneider FJ
    Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
    Lindner DJ; Borden EC; Kalvakolanu DV
    Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of interferons in the treatment of malignant neoplasms.
    Murren JR; Buzaid AC
    Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha, beta, gamma].
    Imanishi J
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2853-8. PubMed ID: 7993128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferons in the management of viral hepatitis.
    Zein NN
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.
    Dash S; Prabhu R; Hazari S; Bastian F; Garry R; Zou W; Haque S; Joshi V; Regenstein FG; Thung SN
    Liver Int; 2005 Jun; 25(3):580-94. PubMed ID: 15910496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferons. New additions and indications for use.
    Stadler R; Ruszczak Z
    Dermatol Clin; 1993 Jan; 11(1):187-99. PubMed ID: 7679614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of combination biotherapy studies: future goals and challenges.
    Gilewski TA; Golomb HM
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):3-10; discussion 38-41. PubMed ID: 1689077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experiences with interferon-alpha and interferon-gamma.
    Steinmann GG; Rosenkaimer F; Leitz G
    Int Rev Exp Pathol; 1993; 34 Pt B():193-207. PubMed ID: 8458713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.